Skip to main content
. 2022 Sep 22;35(11):2122–2132. doi: 10.1021/acs.chemrestox.2c00231

Table 1. Clinical Details of Patients with Confirmed Hypersensitivity to Clavulanic Acid or Tazobactam.

patient ID age gender drug reaction interval (min) reaction study interval (days) reaction clinical diagnosis
P1 44 F 20 240 anaphylaxis clavulanic acid hypersensitive (positive intradermal test)
P2 34 F 10 730 urticaria clavulanic acid hypersensitive (positive intradermal test)
P3 63 M 5 1460 anaphylactic shock clavulanic acid hypersensitive (positive intradermal test)
P4 34 F 12 (days) 450 maculopapular rash, fever tazobactam hypersensitive (positive LTT)